The management of tumor lysis syndrome

Nature Clinical Practice Oncology

Volumn 3, Issue 8, 2006, Pages 438-447

  Rampello, Elvira ^a   Fricia, Tiziana ^a   Malaguarnera, Mariano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; AMMONIUM CHLORATE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; CREATININE; CYTOTOXIC AGENT; DIURETIC AGENT; FUROSEMIDE; GLUCONATE CALCIUM; GLUCOSE; INFUSION FLUID; INSULIN; LACTATE DEHYDROGENASE; LOOP DIURETIC AGENT; MANNITOL; NITROGEN; OXIPURINOL; PHOSPHATE BINDING AGENT; POLYSTYRENESULFONATE SODIUM; POTASSIUM; POTASSIUM CHLORIDE; RASBURICASE; UNINDEXED DRUG; URATE; URATE OXIDASE; UREA;

ACUTE KIDNEY FAILURE; ALKALINIZATION; ALKALOSIS; ANAPHYLAXIS; ANOREXIA; ANURIA; ASYSTOLE; BLOOD CLOTTING DISORDER; BRONCHOSPASM; CALCIFICATION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CREATININE CLEARANCE; DELIRIUM; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; FLACCID PARALYSIS; HALLUCINATION; HEART ARREST; HEART BLOCK; HEART FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATURIA; HEMODIALYSIS; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERREFLEXIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INTESTINE NECROSIS; LABORATORY TEST; LARYNX SPASM; LETHARGY; LEUKEMIA; LYMPHOMA; MEMORY DISORDER; MENTAL DEFICIENCY; MUSCLE CRAMP; MUSCLE SPASM; MUSCLE TWITCH; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; OLIGURIA; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATE INTAKE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; TETANY; TORSADE DES POINTES; TREATMENT INDICATION; TUMOR LYSIS SYNDROME; UREA NITROGEN BLOOD LEVEL; UREMIA; URIC ACID NEPHROPATHY;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; HUMANS; HYPERKALEMIA; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY FAILURE, ACUTE; NEOPLASMS; TUMOR LYSIS SYNDROME;

EID: 33746978287     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0581     Document Type: Review

References (85)

1. Castro MP et al. (1999) Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: A case report and review of the literature. Cancer 85: 1055
2. Jones DP et al. (1995) Tumor lysis syndrome: Pathogenesis and management. Pediatr Nephrol 9: 206-212
3. Co CS et al. (1983) Urinary uric acid excretion in patients with carcinoma of the cervix undergoing intracavitary radium therapy. Radiat Med 1: 245-247
4. Jasek AM and Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47: 129-131
5. Alkhuja S and Ulrich H (2002) Acute renal failure from spontaneous acute tumor lysis syndrome: A case report and review. Ren Fail 24: 227-232
6. Feld J et al. (2000) Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: Case report. Am J Clin Oncol 23: 491-493
7. Agha-Razii M et al. (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 54: 59-63
8. Salkowsky F (1870) Beitrage Zur Kenntins der Leukamie. Virchows Arch Pathol Anat 50: 174-177
9. Bedrna J et al. (1929) harnleiterverschluss nach Bestrahlung chronischer leukämien mit röntgenstrahlen. Med Klin 25: 1700-1701
10. Crittenden DR and Ackerman GL (1977) Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med 137: 97-99
11. Cohen LF et al. (1980) Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma. Am J Med 68: 486-491
12. Hande KR and Garrow GC (1993) Acute tumorlysis syndrome in patients with high grade non-Hodgkin lymphoma. Am J Med 94: 133-139
13. Tsokos GC et al. (1981) Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 60: 218-229
14. Montalban C et al. (1994) Tumor lysis syndrome after treatment of chronic lymphocitic leukaemia with fludarabine. Postgrad Med J 70: 651-652
15. Trendle MC and Tefferi A (1994) Tumor lysis syndrome after treatment of chronic lymphocytic leukemia with cladribine. N Engl J Med 330: 1090
16. Dann EJ et al. (1993) Brief report: Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocitic leukaemia. N Engl J Med 329: 1547-1548
17. Mulligan SP and Dean MG (1994) Fludarabine causing tumor lysis syndrome in chronic lymphocitic leukaemia. Aust NZJ Med 24: 406-407
18. Drakos P et al. (1994) Tumor lysis syndrome in nonhematologic malignancies: Report of a case and review of the literature. Am J Clin Oncol 17: 502-505
19. Cech P et al. (1986) Tumor lysis syndrome after tamoxifen flare. N Engl J Med 315: 263-264
20. Ustundag Y et al. (1997) Acute tumor lysis syndrome associated with paclitaxel. Ann Pharmacother 31: 1548-1549
21. Kalemkerian GP et al. (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103: 363-367
22. Vogelzang NJ et al. (1983) Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma. JAMA 249: 513-514
23. Hussein AM and Feun LG (1990) Tumor lysis syndrome after induction chemotherapy in small-cell lung carcinoma. Am J Clin Oncol 13: 10-13
24. Persons DA et al. (1998) Tumor lysis syndrome and acute renal failure after treatment of non-small cell lung carcinoma with combination irinotecan and cisplatin. Am J Clin Oncol 21: 426-429
25. Barton JC (1989) Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer 64: 738-740
26. Yokoi K et al. (1997) Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis. Am J Clin Oncol 20: 86-89
27. Tomlinson GC and Solberg LA Jr (1984) Acute tumor lysis syndrome with metastatic medulloblastoma: A case report. Cancer 53: 1783-1785
28. Bilgrami SF and Fallon BG (1993) Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 21: 521-524
29. Khan J and Broadbent VA (1993) Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma. Pediatr Hematol Oncol 10: 151-155
30. Khalil A et al. (1998) Fatal acute tumor lysis syndrome following treatment of vulvar carcinoma: Case report. Eur J Gynaecol Oncol 19: 415-416
31. Dirix LY et al. (1991) Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer 67: 2207-2210
32. Wossmann W et al. (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukaemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82: 160-165
33. Baeksgaard L and Sørensen JB (2003) Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol 51: 187-192
34. Hediger MA et al. (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20: 125-133
35. Flombaum CD (2000) Metabolic emergencies in the cancer patient. Semin Oncol 27: 322-334
36. Mattu A et al. (2000) Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 18: 721-729
37. Shiber JR and Mattu A (2003) Serum phosphate abnormalities in the emergency department. J Emerg Med 23: 395-400
38. Jean-Jacques Body and Roger Bouillon (2003) Emergencies of calcium homeostasis. Rev Endocr Metab Disorders 4: 167-175
39. Duncan H and Dixon AS (1960) Gout, familial hypericaemia, and renal disease. Q J Med 29:127-135
40. Wilcox WR et al. (1972) Solubility of uric acid and monosodium urate. Med Biol Eng 10: 522-531
41. Klinenberg JR et al. (1975) Hyperuricemic nephropathy: Pathologic features and factors influencing urate deposition. Nephron 14: 88-98
42. Conger JD and Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59: 786-793
43. Rieselbach RE et al. (1964) Uric acid excretion and renal function in the acute hyperuricemia of leukaemia: Pathogenesis and therapy of uric acid nephropathy. Am J Med 37: 872-884
44. Kelton J et al. (1978) A rapid method for the diagnosis of acute uric acid nephropathy. Arch Int Med 138: 612-615
45. Van Der Klooster JM et al. (2000) Asystole during combination chemotherapy for non-Hodgkin's lymphoma: The acute tumor lysis syndrome. Neth J Med 56: 147-152
46. Albright RC Jr (2001) Acute renal failure: A practical update. Mayo Clin Proc 76: 67-74
47. Cairo MS and Bishop M (2004) Tumor lysis syndrome: New therapeutic strategies and classification. Br J Haematol 127: 3-11
48. Lorigan PC et al. (1996) Tumour lysis syndrome, case report and review of the literature. Ann Oncol 7: 631-636
49. Sallan S (2001) Management of acute tumor lysis syndrome. Semin Oncol 28 (Suppi 5): S9-S12
50. Sewani H and Rabatin JT (2002) Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clin Proc 77: 722-728
51. Kingston ME (1974) Methods of rehydration. J Trop Pediatr Environ Child Health 20: 55-56
52. Lynch RE et al. (1997) Renal and metabolic complications of childhood non-Hodgkin's lymphoma. Semin Oncol 4: 325-334
53. Arrambide K and Toto RD (1993) Tumor lysis syndrome. Semin Nephrol 13: 273-280
54. Conger JD and Falk SA (1997) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59: 786-793
55. Massry SG et al. (1973) Excretion of phosphate and calcium: Physiology of their renal handling and relation to clinical medicine. Arch Intern Med 131: 828-859
56. Monballyu J et al. (1984) Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 22: 47-50
57. DeConti RC and Calabresi P (1966) Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 274: 481-486
58. Hande KR et al. (1981) Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 41: 2273-2279
59. Earll JM and Saavedra M (1983) Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician 28: 147-148
60. Andreoli SP et al. (1986) Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 109: 292-298
61. Pui CH et al. (1997) Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukaemia 11: 1813-1816
62. Greene ML et al. (1969) Urinary xanthine stones - a rare complication of allopurinol therapy. N Engl J Med 280: 426-427
63. Band PR et al. (1970) Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283: 354-357
64. Goldman SC et al. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97: 2998-3003
65. Pui CH et al. (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19: 697-704
66. Leverger G and Patte C (2003) Therapeutic progress in acute lymphoblastic leukemias and stage IV Burkitt-type lymphomas in children. Bull Acad Natl Med 187: 743-755
67. Patte C et al. (2001) European experience in the treatment of hyperuricemia. Semin Hematol 38 (Suppl 10): S9-S12
68. Patte C et al. (2002) Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukaemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 13: 789-795
69. Leach KG et al. (1985) Serial measurement of renal plasma flow. Eur J Nucl Med 11: 33-35
70. Jankovic M et al. (1985) Urate-oxidase as hypouricemic agent in a case of acute tumor lysis syndrome. Am J Pediatr Hematol Oncol 7: 202-204
71. Masera G et al. (1982) Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 100: 152-155
72. Navolanic PM et al. (2003) Elitek-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome. Leukemia 17: 499-514
73. Ganson NJ et al. (2005) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8: 1-10
74. Hammel M et al. (2003) Successful treatment of hyperuricemia with low dose of recombinant urate oxidase in four patients with haematologic malignancy and tumor lysis syndrome. Leukemia 17: 2542-2544
75. McInnes GT et al. (1981) Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 40: 245-249
76. Arellano F and Sacristan JA (1993) Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 27: 337-343
77. Macfarlane RJ et al. (2004) Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr Nephrol 19: 924-927
78. Scott TR et al. (1993) Colonic necrosis following sodium polystyrene sulphonate (Kayexalate)-sorbitol enema in a renal transplant patient: report of a case and review of the literature. Dis Colon Rectum 36: 607-609
79. Altman A (2001) Acute tumor lysis syndrome. Semin Oncol 28 (Suppl 5): S3-S8
80. Jeha S (2001) Tumor Lysis Syndrome. Semin Hematol (Suppl) 10: S4-S8
81. Yarpuzlu AA (2003) A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 333: 1318
82. Hande KR and Garrow GC (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94: 133-139
83. Frisk P et al. (2002) Renal function after autologous bone marrow transplantation in children: A long term prospective study. Bone Marrow Transplant 29: 129-136
84. DuBose TD Jr et al. (1997) Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 29: 793-799
85. Davidson MB et al. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: 546-554